A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

Starting soon · Phase 1/Phase 2

Conditions studied: Major Depressive Disorder

In brief

The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.

Key facts

Study ID

NCT03833206

Run by

BioLite, Inc.

People needed

12

Starts

2027-01-15

Expected to finish

2028-02-28

Last updated by the study team

2026-04-20

Who can join

Age: 21 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Have a current or previous diagnosis of or history consistent with obsessive-compulsive disorder, posttraumatic stress disorder, bipolar I or II, manic or hypomanic episodes, schizophrenia, major Axis II disorders which might compromise the study, or major depression with psychotic symptoms, as assessed using the MINI International Neuropsychiatric Interview (MINI Plus).
• Have a documented history of an intellectual disability.
• Use of any antidepressant medication in the last 2 weeks before visit 1 (4 weeks for fluoxetine).
• Currently being treated with tamoxifen.
• Subjects who were non-responsive to two or more courses of antidepressant medications given at an adequate dosage* for symptom treatment within four weeks, or by the judgment of the investigator considered to have treatment resistant depression (TRD), or a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or psychosurgery within the last year.
• Have a history of any seizure disorder.
• Any clinically significant abnormal vital sign, ECG, or laboratory values as determined by the investigator which might interfere with the study.
• Have a high suicidal risk as assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). High suicidal risk is indicated by:
• A positive response to question 4 or 5, indicating endorsement of suicidal ideation with at least some intent to act in the past month; and/or
• A positive response to part two of question 6, indicating the presence of any suicidal behavior in the past 3 months.
• Have a history of substance dependence/abuse** within the past 6 months or a positive drug screen result during the screening period.
• Have a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions.
• * An adequate dosage of the antidepressant medication is defined as the average of the usual dose (mg/day) recommended in American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. E.g. the usual dose of Citalopram is 20-60 mg/day, the adequate dosage is 40 mg/day.
• ** Tobacco is excluded here, and alcohol abuse is defined as average pure alcohol intake is more than 112 g (for male) or 56 g (for female) per week and/or with Alcohol withdrawal syndrome. Pure alcohol intake =% (Concentration or alcohol content) x c.c. (volume)x 0.79 (density of alcohol). Result of serum ethanol test should be equal to or lower than 10.0 mg/dL to be determined as eligible for the trial. If test result is between 10.1 to 29.9 mg/dL, only one re-test is allowed per subject to meet the criterion. Subject with test result equal to or higher than 30.0 mg/dL is to be excluded.

Where it is running

• Cedars-Sinai Health System — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.